The phosphoproteome of ovarian carcinoma delineates signaling signatures and potentially druggable targets across histotype stages
Lucas Werner, Parisa Esmaeili, Ella Ittner, Hugo Swenson, Anikó Kovács, Claudia Mateoiu, Pernilla Dahm-Kähler, Per Karlsson, Toshima Parris, Fredrik Levander, Khalil Helou · 2026
Read The phosphoproteome of ovarian carcinoma delineates signaling signatures and potentially druggable targets across histotype stages by Lucas Werner, Parisa Esmaeili, Ella Ittner, Hugo Swenson, Anikó Kovács, Claudia Mateoiu, Pernilla Dahm-Kähler, Per Karlsson, Toshima Parris, Fredrik Levander, Khalil Helou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13476440.txt.
Description
Lucas Werner and co-authors map protein switches in ovarian cancer in a 2026 study. Ovarian tumors relapse often and kill at high rates, yet treatment still leans on surgery and platinum drugs for all types. Reading phosphorylation, the chemical switches that steer cell signals, could split the disease into truer groups.
Across one hundred eighty patients and four tumor types, the team found switch sites tied to cancer growth, each with its own pattern by type and stage. Enzyme activity profiles carried type specific signatures, and some switches forecast patient outlook. The authors say the map points to drug targets and supports building treatments matched to each tumor type rather than one recipe for all.
Catalog record
| CREATOR | Lucas Werner, Parisa Esmaeili, Ella Ittner, Hugo Swenson, Anikó Kovács, Claudia Mateoiu, Pernilla Dahm-Kähler, Per Karlsson, Toshima Parris, Fredrik Levander, Khalil Helou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |